<DOC>
	<DOCNO>NCT00744185</DOCNO>
	<brief_summary>The investigator observe Propranolol , beta-blocker commonly use child efficient control growth alarm hemangiomas face . The primary objective study determine efficiency 1 month-early treatment propranolol infant age less 4 month affect hemangioma without consequence vital functional structure justify corticosteroid . The secondary objective : - kinetic hemangioma evolution infant treat propranolol - Observance - Safety</brief_summary>
	<brief_title>Propranolol Capillary Hemangiomas</brief_title>
	<detailed_description>Infantile hemangioma frequent vascular tumor ( 4 à 10 % neonate ) correspond 100 new case per year dermatology consultation CHU Bordeaux . Hemangiomas characteristic clinical course mark early proliferation 3 12 month follow slow spontaneous involution 3 7 year . Occasionally , well esthetical damage , hemangioma may impair vital structure , ulcerate , bleed , cause high-output cardiac failure significant structural abnormality . Standard treatment ( corticotherapy , interferon , vincristine… ) lead stagnation hemangioma case , frequent side effect . We observe Propranolol , beta-blocker usually use neonate could lead decreased volume serious haemangioma face ( article publish New England Journal Medicine ) . In study , propose determine efficiency 1 month-early treatment propranolol neonate age less 4 month affect non alarm hemangioma justify corticotherapy . This double blind randomize placebo control study propranolol . Infants recruit dermatology consultation CHU Bordeaux . After verification eligibility criterion inform consent legal surrogate , infant randomize receive either propranolol either placebo . The infant observe 1 month accord follow visit .</detailed_description>
	<mesh_term>Hemangioma</mesh_term>
	<mesh_term>Hemangioma , Capillary</mesh_term>
	<mesh_term>Port-Wine Stain</mesh_term>
	<mesh_term>Propranolol</mesh_term>
	<criteria>Infant age less 4 month Infant one hemangioma size 1 cm diameter Infant threaten vital functional structure treatment would propose Informed consent Patient social insurance . Alarming hemangioma ( ) ( complicate form localization risk ) Cardiac pathology ( cardiac malformation , heart failure , cardiac arrhythmia , pulmonary hypertension ) Asthma Bronchopulmonary dysplasia Bronchiolitis Raynaud syndrome Phéochromocytoma Development serious form hemangioma ( bleeding , necrosis , ulceration , infection , respiratory distress ) require standard treatment</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>4 Months</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>infantile capillary hemangioma</keyword>
	<keyword>propranolol</keyword>
	<keyword>ultrasonography</keyword>
</DOC>